Neurofit (Co-CEOs Bin Jun-gil and Kim Dong-hyun), an artificial intelligence (AI) company specializing in brain disease diagnosis and treatment, announced on the 24th that it will participate in the 2025 Alzheimer's Association International Conference (AAIC 2025) and present its main brain imaging analysis solutions.
At this conference, Neurophyt will unveil 'Neurophet AQUA AD', an AI-based software specialized in dementia treatment prescription and treatment response monitoring. The solution is designed to precisely analyze the brain status before and after anti-amyloid antibody treatment administration through quantitative analysis of magnetic resonance imaging (MRI) and positron emission tomography (PET) images.
Recently, as global development of Alzheimer's disease treatment drugs is actively underway, the demand for solutions that can evaluate the efficacy and side effects of related treatments based on images is increasing. In particular, for major treatments such as recanemab (product name Rekembi) and donanemab (product name Kisunla), the importance of the function to predict and manage side effects in advance is being highlighted.
At this conference, Neurofit will introduce its main solutions, including ▲ Neurofit Aqua, a brain nerve degeneration analysis software, and ▲ Neurofit Scale Pet, a PET image quantitative analysis software, through its exhibition booth. It also plans to explore business collaboration possibilities with global pharmaceutical companies and medical technology companies and build a network with key experts in the field of neurology.
At the conference, Co-CEO Bin Jun-gil will present on the topic of ‘Neurofit in the Era of Alzheimer’s Disease Paradigm Shift: The Journey to IPO and Beyond’. Through this, he plans to share the company’s technological vision and growth strategy.
Neurofit said, “Neurofit Aqua AD is a brain imaging biomarker-based treatment response analysis technology that is receiving requests for cooperation both domestically and internationally,” and “We plan to expand global collaboration and accelerate product development and commercialization through our participation in AAIC 2025.”
- See more related articles
You must be logged in to post a comment.